Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today announced that the company received a letter from the U.S. Food and Drug Administration (FDA) on January 25, 2022 placing a full clinical hold on atuzaginstat’s (COR388) Investigational New...

Click to view original post